19 July 2018

EQUITIES

SCGB MK Price (at 10:40, 19 Jul 2018 GMT)		Neutral RM1.95
Valuation - PER	RM	1.66-2.37
12-month target	RM	2.00
Upside/Downside	%	+2.6
12-month TSR	%	+7.0
Volatility Index	I	_ow/Medium
GICS sector	C	apital Goods
Market cap	RMm	2,521
Market cap	US\$m	583
Free float	%	27
30-day avg turnover	US\$m	0.2
Number shares on issue	m	1,293

Investment fundamentals

Year end 31 Dec		2017A	2018E	2019E	2020E
Revenue	m	2,076.3	2,162.1	2,583.0	2,311.7
EBITDA	m	202.4	222.2	259.0	252.3
EBIT	m	164.6	178.6	208.6	198.3
Reported profit	m	137.8	149.0	173.4	168.4
Adjusted profit	m	137.8	149.0	173.4	168.4
EPS rep	sen	10.7	11.5	13.4	13.0
EPS rep growth	%	11.9	8.1	16.4	-2.9
EPS adj	sen	10.7	11.5	13.4	13.0
EPS adj growth	%	11.9	8.1	16.4	-2.9
PER rep	Х	18.3	16.9	14.5	15.0
PER adj	Х	18.3	16.9	14.5	15.0
Total DPS	sen	7.0	8.0	9.0	10.0
Total div yield	%	3.6	4.1	4.6	5.1
ROA	%	9.5	9.7	11.6	10.9
ROE	%	26.3	25.9	27.6	24.9
EV/EBITDA	Х	10.6	9.7	8.4	8.6
Net debt/equity	%	-63.5	-45.0	-48.9	-79.4
P/BV	Х	4.6	4.2	3.8	3.6

SCGB MK rel KLCI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018 (all figures in MYR unless noted)

Macquarie Governance and Risk Score (MGRS)

On our proprietary <u>Governance and Risk Score</u>
Sunway Construction Group scores in the third quartile of our current universe coverage.

Analysts

Macquarie Capital Securities (Malaysia) Sdn. Bhd.



Aiman Mohamad +60 3 2059 8986 aiman.mohamad@macquarie.com

Malaysia

Sunway Construction Group Insufficient fuel for take-off

Key points

- We downgrade SunCon to Neutral (from Outperform), with a reduced target price of RM2.00 (from RM2.60).
- SunCon's heavy reliance (70% of outstanding orderbook) on government projects poses a threat to its orderbook outlook, in our view.
- We cut our estimates following a revision in the FY18E orderbook replenishment target from RM2bn to RM1.5bn.

Event

• Sunway Construction (SunCon) has relied heavily on government projects in its previous orderbook replenishment exercises. As the new government begins to clamp down on future spending, this poses a risk to SunCon's orderbook outlook. We estimate c.70% of its outstanding orderbook came from the government and its GLCs. Against this backdrop, we downgrade SunCon to Neutral and revise our TP by -23% from RM2.60 to RM2.00. Among other adjustments, we reduce our FY18E order win target from RM2bn to RM1.5bn. Our new TP of RM2.00 implies a 15x multiple to SunCon's FY19E EPS, a touch below its long-term fwd-PE average of 16x.

Impact

- Earnings to peak in FY19E; more support from Sunway Berhad going ahead. SunCon recorded order wins of >RM2.5bn in FY15-17 which now provide earnings visibility to the group until FY20E. However, with order wins of RM1.5bn/FY in FY18-20E, we believe earnings will peak in FY19E. YTD SunCon recorded an order win of RM842mn, with at least RM700mn coming from its parent Sunway Berhad (Sunway). SunCon targets to secure another c.RM800mn in new orders to meet its FY18E order win target of RM1.5bn. Based on Sunway's project pipeline, it is looking to build three new medical centres and a mall in 2019, with a combined value of c.RM900mn we believe these projects will likely be awarded to SunCon in FY19E. Going forward SunCon is also planning to venture into projects in the ASEAN region, given the potential slowdown in Malaysian construction sector.
- Limited downside despite looming LRT3 and MRT2 cost cuts. Based on our estimates, every 10% change in LRT3 and MRT2 contract values would reduce our fair value by -1.6% and -1.2%, respectively. However, we estimate SunCon to pay a DPS of 8.0sen in FY18E, tantamount to a 4.1% dividend yield, which should provide additional downside support to the share price.

Earnings and target price revision

Following earnings adjustments, we lower our FY18-20E EPS
 -17%/-20%/-34%, respectively. TP revised to RM2.00 from RM2.60 previously.

Price catalyst

- 12-month price target: RM2.00 based on a PER methodology.
- Catalyst: Further clarity by government on LRT3 and MRT2 cost cuts.

Action and recommendation

Downgrade to Neutral.

Analysis

We downgrade SunCon to Neutral from Outperform and reduce our TP from RM2.60 to RM2.00 due to the following changes:

- Revised FY18E order wins from RM2bn to RM1.5bn as we believe it will be challenging for SunCon to
 obtain order wins of such quantum due to the government's reduction in spending, with every
 RM100mn change in order wins (from our base case) changing our fair value by 1%;
- From the amount above, we reduced SunCon's FY18E precast order win from RM250mn to RM100mn given the lack of precast orders recorded YTD. This brings a significant impact to the earnings given that precast products deliver higher margins with a higher turnover; and
- We spread out the construction progress of LRT3 from 3.5 years to 4.5 years following MoF's recent
 announcement to extend the project's timeline to reduce overtime payments. However we have not
 factored in the reduction in LRT3 and MRT2 (potentially) project value, until the figures are finalised by
 the government. Based on our estimates, every 10% change in LRT3 and MRT2 contract values, will
 reduce our fair value by -1.6% and -1.2%, respectively.

Fig 1 SunCon valuation

Item	Valuation Method	Stake	New Estimates (RM 'mil)	Old Estimates (RM 'mil)	Change (%)
Construction and Precast	PER of 14x in FY19E	100%	2,313	3,069	-25%
FY18E estimated net cash			270	291	-7%
Valuation			2,583	3,360	-23%
No. of shares ('mil)			1,293	1,293	0%
Target Price (RM)	·		2.00	2.60	-23%

Scenario	Bear	Base	Bull
Fair value (RM)	1.66	2.00	2.37
Implied PE	12x	15x	17x
Upside (%)	-14.6%	3.1%	22.2%
Dividend Yield (%)	4.1%	4.1%	4.1%
TSR (%)	-10.5%	7.2%	26.3%
Key Assumptions			
Orderbook replenishment FY18E	1,000	1,500	2,000
Orderbook replenishment FY19E	1,000	1,500	2,000
Target PE	12x	14x	16x


Source: Company data, Bloomberg, Macquarie Research, July 2018; share price as at 19 July 2018 close

Fig 2 Orderbook and target PE sensitivity

FY18E-19E Orderbook Replenishment (RM 'mil) 2,000 2.500 3.000 3.500 4,000 12x 1.66 1.70 1.74 1.79 1.83 13x 1.78 1.82 1.87 1.92 1.96 Target PE 14x 1.90 1.95 2.00 2.05 2.10 15x 2.02 2.07 2.13 2.18 2.23 2.25 16x 2.14 2.19 2.31 2.37 2.51 17x 2.26 2.32 2.38 2.44

Source: Company data, Macquarie Research, July 2018

Fig 3 SunCon's fwd-rolling PE



Source: Company data, Macquarie Research, July 2018


19 July 2018

Financials

Prior to FY18E, SunCon has been registering order wins of above RM2.5bn/FY in FY15-17.Based on our order win targets of RM1.5bn/FY in FY18-20E, we believe SunCon's earnings will peak in FY19E. Going ahead, we estimate margins will remain stable as the higher margins from construction is offset by the lower margins from the precast division. The precast division is facing headwinds from higher material costs as well as lower ASPs due to the stiff competition in the HDB market.


According to management, it will continue to bring dividend growth to investors going ahead, given the company's strong cash balance. In FY18E, we estimate a dividend payout of 69% tantamount to dividend per share of 8.0sen.

Fig 4 Earnings to peak in FY19E




Source: Company data, Macquarie Research, July 2018

Fig 5 Dividend outlook still on an uptrend




Source: Company data, Macquarie Research, July 2018

Fig 6 Strong FCF balance brings headroom for dividend growth



Source: Company data, Macquarie Research, July 2018

Fig 7 EBIT contribution by division



Source: Company data, Macquarie Research, July 2018

Fig 8 Change in estimates

RM 'mil	Nev	v estimate:	S	Old	Old estimates			Change in estimates		
KIVI IIIII	FY18E	FY19E	FY20E	FY18E	FY19E	FY20E	FY18E	FY19E	FY20E	
Revenue	2,162	2,583	2,312	2,578	2,959	2,741	-16%	-13%	-16%	
EBIT	179	209	198	218	259	290	-18%	-20%	-32%	
Profit before tax	189	217	211	229	270	305	-17%	-20%	-31%	
Adjusted net profit	149	173	168	181	216	255	-17%	-20%	-34%	
Diluted EPS (sen)	12	13	13	14	17	20	-17%	-20%	-34%	


Source: Macquarie Research, July 2018

Fig 9 Macquarie vs. consensus

DM Incil	M	lacquarie		C	onsensus		D	<u>Difference</u>		
RM 'mil	FY18E	FY19E	FY20E	FY18E	FY19E	FY20E	FY18E	FY19E	FY20E	
Revenue	2,162	2,583	2,312	2,587	2,876	2,849	-16%	-10%	-19%	
EBIT	179	209	198	216	240	248	-17%	-13%	-20%	
Profit before tax	189	217	211	223	250	263	-16%	-13%	-20%	
Adjusted net profit	149	173	168	171	191	204	-13%	-9%	-18%	
Diluted EPS (sen)	12	13	13	13	15	16	-13%	-10%	-16%	

Source: Bloomberg, Macquarie Research, July 2018

Fig 10 Order wins - history and forecast



Source: Company data, Macquarie Research, July 2018

Fig 11 YTD order wins

Project	Value (RM 'mil)
Sunw ay Medical Centre Seberang Jaya	180
Sunw ay Carnival Extension	274
Sunw ay GEOLake	223
Others (Inhouse)	35
Precast	55
Piling	75
Total	842

Source: Company data, July 2018

Fig 12 SunCon's orderbook

Project	Completion Period	Contract Value (RM 'mil)	Outstanding value (RM 'mil)	% Completion
External				
Putrajaya Parcel F	1Q19	1,610	707	56%
KLCC (NEC + 2 + 2A)	2Q18	646	98	85%
HUKM (MEP works)	2Q18	66	45	32%
International School of Kuala Lumpur	2Q18	268	133	50%
Gas District Cooling (Plant 1)	3Q18	152	102	33%
PP1AM Kota Bharu	1Q20	582	540	7%
Warehouse in Shah Alam	3Q19	70	70	0%
MRT V201 (Sg. Buloh - Persiaran Dagang)	2Q21	1,213	871	28%
MRT V201 - Advance Works	1Q18	53	19	64%
SUKE & DASH (Piling)	2Q18	34	21	38%
BBCC (Piling)	1Q18	108	78	28%
LRT3 (GS07 & GS08)	4Q20	2,178	2,150	1%
·	Total	6,980	4,834	31%
Internal		•		
Sunway Velocity Hotel + Office	4Q17	101	3	97%
Sunway Velocity Medical Centre	4Q18	185	128	31%
Sunway Medical Centre Phase 4	1Q19	428	383	11%
Sunway Iskandar Citrine Service Apartment	1Q18	213	12	94%
Sunway Geo Retail Shops & Flexi Suites Phase 2	1Q18	244	19	92%
Sunway Iskandar - Emerald Residences	1Q18	175	32	82%
Sunway Iskandar - 88 units shoplots	2Q18	57	13	77%
Sunway Iskandar - Big Box	1Q18	100	70	30%
Sunway Serene	4Q20	449	426	5%
Sunway Carnival 2	4Q20	274	274	0%
SunGeo Lake	2Q21	223	223	0%
	Total	2,226	1,360	39%
Precast				
Singapore HDB	2Q19	846	252	70%
	Total	846	252	70%
	Grand Total	10,052	6,446	36%

Macquarie Quant View


The quant model currently holds a neutral view on Sunway Construction Group. The strongest style exposure is Valuations, indicating this stock is under-priced in the market relative to its peers. The weakest style exposure is Price Momentum, indicating this stock has had weak medium to long term returns which often persist into the future.

1145/1957

Global rank in Capital Goods

% of BUY recommendations 54% (7/13) Number of Price Target downgrades 3

Number of Price Target downgrades 3 Number of Price Target upgrades 0




Displays where the company's ranked based on the fundamental consensus Price Target and Macquarie's Quantitative Alpha model.

Two rankings: Local market (Malaysia) and Global sector (Capital Goods)


Macquarie Alpha Model ranking

A list of comparable companies and their Macquarie Alpha model score (higher is better).




Factors driving the Alpha Model

For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score.




Macquarie Earnings Sentiment Indicator

The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below.




Drivers of Stock Return

Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple.




What drove this Company in the last 5 years

Which factor score has had the greatest correlation with the company's returns over the last 5 years.



How it looks on the Alpha model

A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market.



Source (all charts): FactSet, Thomson Reuters, and Macquarie Research. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (cpg@macquarie.com)

Sunway Construction Interim Results	Group	2H/17A	1H/18E	trai, Tarç 2H/18E	1H/19E	Profit & Loss		2017A	2018E	2019E	2020E
interim Results		20/17A	III/ IOE	2H/10E	111/19	FIGHT & LOSS		2017A	2010	2019E	2020
Revenue	m	1,240	973	1,189	1,162	Revenue	m	2,076	2,162	2,583	2,312
Gross Profit	m	126	100	122	117	Gross Profit	m	202	222	259	252
Cost of Goods Sold	m	1,113	873	1,067	1,046	Cost of Goods Sold	m	1,874	1,940	2,324	2,059
EBITDA	m	126	100	122	117	EBITDA	m	202	222	259	252
Depreciation	m	19	20	24	23	Depreciation	m	38	44	50	54
Amortisation of Goodwill	m	0	0	0	0	Amortisation of Goodwill	m	0	0	0	0
Other Amortisation EBIT	m m	107	80	98	94	Other Amortisation EBIT	m m	1 65	1 79	209	1 98
Net Interest Income	m	-4	-1	-1	-1	Net Interest Income	m	-6	-3	-3	-3
Associates	m	1	Ö	1	0	Associates	m	2	1	0	0
Exceptionals	m	0	0	0	0	Exceptionals	m	0	0	0	0
Forex Gains / Losses	m	Ō	0	0	Ō	Forex Gains / Losses	m	0	0	0	0
Other Pre-Tax Income	m	8	5	6	5	Other Pre-Tax Income	m	13	12	11	15
Pre-Tax Profit	m	112	85	104	98	Pre-Tax Profit	m	174	189	217	211
Tax Expense	m	-21	-18	-22	-20	Tax Expense	m	-36	-40	-43	-42
Net Profit	m	92	67	82	78	Net Profit	m	138	149	173	168
Minority Interests	m	-0	-0	-0	-0	Minority Interests	m	-0	-0	-0	-0
Reported Earnings Adjusted Earnings	m m	91 91	67 67	82 82	78 78	Reported Earnings Adjusted Earnings	m m	138 138	149 149	173 173	168 168
EPS (rep)	sen	7.1	5.2	6.3	6.0	EPS (rep)	sen	10.7	11.5	13.4	13.0
EPS (adj)	sen	7.1	5.2	6.3	6.0	EPS (adj)	sen	10.7	11.5	13.4	13.0
EPS Growth yoy (adj)	%	34.8	44.2	-10.3	16.4	EPS Growth (adj)	%	11.9	8.1	16.4	-2.9
						PE (rep)	X	18.3	16.9	14.5	15.0
						PE (adj)	Х	18.3	16.9	14.5	15.0
EBITDA Margin	%	10.2	10.3	10.3	10.0	Total DPS	sen	7.0	8.0	9.0	10.0
EBIT Margin	%	8.6	8.3	8.3	8.1	Total Div Yield	%	3.6	4.1	4.6	5.1
Earnings Split	%	66.3	45.0	55.0	45.0	Basic Shares Outstanding	m	1,293	1,293	1,293	1,293
Revenue Growth	%	26.0	16.3	-4.1	19.5	Diluted Shares Outstanding	m	1,293	1,293	1,293	1,293
EBIT Growth	%	30.1	38.9	-8.0	16.8						
Profit and Loss Ratios		2017A	2018E	2019E	2020E	Cashflow Analysis		2017A	2018E	2019E	2020E
Revenue Growth	%	16.1	4.1	19.5	-10.5	EBITDA	m	202	222	259	252
EBITDA Growth	%	7.5	9.8	16.6	-2.6	Tax Paid	m	-37	-40	-43	-42
EBIT Growth	%	10.3	8.5	16.8	-4.9	Chgs in Working Cap	m	112	-101	13	155
Gross Profit Margin	%	9.7	10.3	10.0	10.9	Net Interest Paid	m	7	9	8	12
EBITDA Margin	%	9.7	10.3	10.0	10.9	Other	m	-222	0	0	0
EBIT Margin	% %	7.9 6.6	8.3 6.9	8.1 6.7	8.6 7.3	Operating Cashflow Acquisitions	m m	63 0	90 0	237 0	377 0
Net Profit Margin Payout Ratio	%	65.7	69.4	67.1	76.8	Capex	m	-55	-106	-108	-56
EV/EBITDA	76 X	10.6	9.7	8.4	8.6	Asset Sales	m	6	0	0	0
EV/EBIT	X	13.0	12.1	10.4	10.9	Other	m	83	0	0	0
						Investing Cashflow	m	35	-106	-108	-56
Balance Sheet Ratios						Dividend (Ordinary)	m	-71	-97	-110	-123
ROE	%	26.3	25.9	27.6	24.9	Equity Raised	m	-1	0	0	0
ROA	%	9.5	9.7	11.6	10.9	Debt Movements	m	-2	-24	6	6
ROIC	%	79.9	69.8	50.6	47.2	Other	m	-0	0	0	0
Net Debt/Equity	%	-63.5	-45.0	-48.9	-79.4	Financing Cashflow	m	-74	-121	-104	-117
Interest Cover Price/Book	X	27.1 4.6	65.6 4.2	72.9 3.8	66.0 3.6	Net Chg in Cash/Debt	m	20	-107	57	238
Book Value per Share	Х	0.4	0.5	0.5	0.5	_					
						Free Cashflow	m	8	-16	129	321
						Balance Sheet		2017A	2018E	2019E	2020E
						Cash	m	487	380	437	675
						Receivables	m	1,066	1,037	991	823
						Inventories	m	24	25	30	27
						Investments	m	150	176	105	0 157
						Fixed Assets	m	150 4	176 4	195 4	157 4
						Intangibles Other Assets	m	156	156	156	156
						Total Assets	m m	1,887	1,778	1,813	1,842
						Payables	m	794	664	637	621
						Short Term Debt	m	135	110	116	122
						Long Term Debt	m	0	0	0	0
						Provisions	m	0	Ō	0	Ō
						Other Liabilities	m	403	403	403	403
						Total Liabilities	m	1,332	1,178	1,156	1,146
						Shareholders' Funds	m	592	637	694	733
						Minority Interests	m	1	1	1	1
						Other	m	-38	-38	-38 657	-38
						Total S/H Equity Total Liab & S/H Funds	m m	555 1,887	600 1,778	657 1,813	696 1,842
								1,007	.,. 70	1,010	1,072
All figures in MYR unless noted. Source: Company data, Macqua		rch. July 201	18								
		,, _0	-								

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand

Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield, which is currently around 9%.

Macquarie - Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return

Neutral (Hold) – return within 5% of Russell 3000 index

Underperform (Sell)– return >5% below Russell 3000 index return

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

Medium – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

Low – stock should be expected to move up or down at least 15–25% in a year.

* Applicable to Asia/Australian/NZ/Canada stocks

Recommendations – 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 30 June 2018

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	52.87%	61.26%	48.86%	47.54%	69.86%	46.61%	(for global coverage by Macquarie, 3.51% of stocks followed are investment banking clients)
Neutral	34.10%	27.25%	36.36%	46.72%	21.92%	43.22%	(for global coverage by Macquarie, 2.10% of stocks followed are investment banking clients)
Underperform	13.03%	11.49%	14.77%	5.74%	8.22%	10.17%	(for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)



(all figures in MYR currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018

12-month target price methodology

SCGB MK: RM2.00 based on a PER methodology

Company-specific disclosures:

SCGB MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

Date	Stock Code (BBG code)	Recommendation	Target Price
19-Apr-2018	SCGB MK	Outperform	RM2.60
06-Oct-2017	SCGB MK	Outperform	RM2.80
26-Apr-2017	SCGB MK	Outperform	RM2.50
03-Sep-2016	SCGB MK	Outperform	RM1.90
11-Mar-2016	SCGB MK	Outperform	RM1.67

Target price risk disclosures:

SCGB MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd;
Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ)
Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie
Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959

Macquarie Research Sunway Construction Group

(Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

Country-specific disclaimers:

Australia: În Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund, and (ii) participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. This research is distributed in the United States, as third party research by Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of Financial Industry Regulatory Authority and the Securities Investor Protection Corporation. Macquarie Capital Markets North America Ltd. accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd. in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd. should do so with Macquarie Capital Markets North America Ltd. This research is intended for distribution in the United States only to major Institutional Investors (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended) and is not intended for the use of any person or entity that is not a major institutional investor. Research analysts of Macquarie Capital Markets Canada Ltd. are not registered/qualified as research analysts with FINRA. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd. is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai-iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002001000.

South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAČ-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group



Equities

Asia Research

(852) 3922 3583
(813) 3512 6695
(65) 6601 0182

Automobiles, Auto Parts

 Janet Lewis (China, Japan)
 (813) 3512 7856

 Allen Yuan (China)
 (8621) 2412 9009

 James Hong (Korea)
 (822) 3705 8661

 Amit Mishra (India)
 (9122) 6720 4084

Banks and Financials

Scott Russell (Asia) (852) 3922 3567 Dexter Hsu (China, Taiwan) (8862) 2734 7530 Keisuke Moriyama (Japan) (813) 3512 7476 Chan Hwang (Korea) (822) 3705 8643 Suresh Ganapathy (India) (9122) 6720 4078 Jayden Vantarakis (Indonesia) (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 Ken Ang (Singapore) Peach Patharavanakul (Thailand) (65) 6601 0836 (662) 694 7753

Basic Materials

 Yasuhiro Nakada (Japan)
 (813) 3512 7862

 Anna Park (Korea)
 (822) 3705 8669

 Sumangal Nevatia (India)
 (9122) 6720 4093

 Jayden Vantarakis (Indonesia)
 (6221) 2598 8310

 Farrah Aqlima (Malaysia)
 (603) 2059 8987

Conglomerates

 David Ng (China, Hong Kong)
 (852) 3922 1291

 Conrad Werner (Singapore)
 (65) 6601 0182

 Gilbert Lopez (Philippines)
 (632) 857 0892

Consumer, Gaming

(852) 3922 4068 Linda Huang (Asia) (852) 3922 1130 Zibo Chen (China, Hong Kong) Terence Chang (China, Hong Kong) (852) 3922 3581 Sunny Chow (China, Hong Kong) Stella Li (China, Taiwan) (852) 3922 3768 (8862) 2734 7514 Leon Rapp (Japan) (813) 3512 7879 Kwang Cho (Korea) (822) 3705 4953 Amit Sinha (India) (9122) 6720 4085 Karisa Magpayo (Philippines)
Chalinee Congmuang (Thailand) (632) 857 0899 (662) 694 7993 Robert Pranata (Indonesia) (6221) 2598 8366 Richardo Walujo (Indonesia) (6221) 2598 8369 Denise Soon (Malaysia) (603) 2059 8845

Emerging Leaders

 Jake Lynch (Asia)
 (852) 3922 3583

 Kwang Cho (Korea)
 (822) 3705 4953

 Corinne Jian (Greater China)
 (8862) 2734 7522

 Conrad Werner (ASEAN)
 (65) 6601 0182

 Bo Denworalak (Thailand)
 (662) 694 7774

Infrastructure, Industrials, Transportation

 Patrick Dai (China)
 (8621) 2412 9082

 Eric Zong (China, Hong Kong)
 (852) 3922 4749

 Kunio Sakaida (Japan)
 (813) 3512 7873

 James Hong (Korea)
 (822) 3705 8661

 Corinne Jian (Taiwan)
 (8862) 2734 7522

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Azita Nazrene (ASEAN)
 (65) 6601 0560

Internet, Media and Software

 Wendy Huang (Asia)
 (852) 3922 3378

 Marcus Yang (Greater China)
 (8862) 2734 7532

 David Gibson (Japan)
 (813) 3512 7880

 Alankar Garude (India)
 (9122) 6720 4134

Oil, Gas and Petrochemicals

 Aditya Suresh (Asia)
 (852) 3922 1265

 Anna Park (Asia)
 (822) 3705 8669

 Yasuhiro Nakada (Japan)
 (813) 3512 7862

 Corinne Jian (Taiwan)
 (8862) 2734 7522

 Ben Shane Lim (Malaysia)
 (603) 2059 8868

 Yupapan Polpornprasert (Thailand)
 (662) 694 7729

Pharmaceuticals and Healthcare

 Corinne Jian (China)
 (8862) 2734 7522

 Alankar Garude (India)
 (9122) 6720 4134

 Richardo Walujo (Indonesia)
 (6221) 259 88 369

Property, REIT

Tuck Yin Soong (Asia, Singapore) (65) 6601 0838 David Ng (China, Hong Kong) (852) 3922 1291 Kelvin Tam (China) (852) 3922 1181 (813) 3512 7476 (813) 3512 7474 Keisuke Moriyama (Japan) Tomovoshi Omuro (Japan) Abhishek Bhandari (India) (9122) 6720 4088 (603) 2059 8986 Aiman Mohamad (Malaysia) Kervin Sisayan (Philippines) (632) 857 0893 Richard Danusaputra (Indonesia) (6221) 2598 8368

Technology

Damian Thong (Asia, Japan) (813) 3512 7877 Allen Chang (Greater China) (852) 3922 1136 Jeffrey Ohlweiler (Greater China) (8862) 2734 7512 Chris Yu (Greater China) (8621) 2412 9024 Kaylin Tsai (Greater China) (8862) 2734 7523 Lynn Luo (Greater China) (8862) 2734 7534 (8862) 2734 7515 Patrick Liao (Greater China) Verena Jeng (Greater China) (852) 3922 3766 Daniel Kim (Korea) (822) 3705 8641 (9122) 6720 4088 (603) 2059 8987 Abhishek Bhandari (India) Farrah Aqlima (Malaysia)

Telecoms

Allen Chang (Greater China) Prem Jearajasingam (ASEAN) Kervin Sisayan (Philippines) Nathania Nurhalim (Indonesia) (852) 3922 1136 (603) 2059 8989 (632) 857 0893 (6221) 2598 8365

Utilities, Renewables

 Hiroyuki Sakaida (Japan)
 (813) 3512 6695

 Patrick Dai (China)
 (8621) 2412 9082

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Karisa Magpayo (Philippines)
 (632) 857 0899

Quantitative, CPG

 Gurvinder Brar (Global)
 (44 20) 3037 4036

 John Conomos (Asia)
 (612) 8232 5157

 Alvin Chao (Asia)
 (852) 3922 1108

 Tracy Chow (Asia)
 (852) 3922 4285

 Ying Ying Hou (Asia)
 (852) 3922 5422

Strategy, Country

Viktor Shvets (Asia, Global)
David Ng (China, Hong Kong)
Hiroyuki Sakaida (Japan)
Chan Hwang (Korea)
Jeffrey Ohlweiler (Taiwan)
Inderjeetsingh Bhatia (India)
Jayden Vantarakis (Indonesia)
Anand Pathmakanthan (Malaysia)
Gilbert Lopez (Philippines)
Conrad Werner (ASEAN, Singapore)
Peach Patharavanakul (Thailand)

Find our research at

Macquarie: www.macquarieresearch.com Thomson: www.thomson.com/financial Reuters: www.knowledge.reuters.com MAC GO

Factset: http://www.factset.com/home.aspx

CapitalIQ www.capitaliq.com
Email macresearch@macquarie.com for access

Asia Sales

Regional Heads of Sales

Miki Edelman (Global) (1 212) 231 6121 Amelia Mehta (Asia) (65) 6601 0211 Jeffrey Shiu (China, Hong Kong) (852) 3922 2061 Sandeep Bhatia (India) (9122) 6720 4101 (41 22) 818 7712 Thomas Renz (Geneva) (813) 3512 7823 Tomohiro Takahashi (Japan) John Jay Lee (Korea) (822) 3705 9988 Nik Hadi (Malaysia) (603) 2059 8888 Gino C Rojas (Philippines) (632) 857 0861

Regional Heads of Sales cont'd

 Paul Colaco (San Francisco)
 (1 415) 762 5003

 Angus Kent (Thailand)
 (662) 694 7601

 Ben Musgrave (UK/Europe)
 (44 20) 3037 4882

 Christina Lee (UK/Europe)
 (44 20) 3037 4873

Sales Trading

Adam Zaki (Asia) (852) 3922 2002 Stanley Dunda (Indonesia) (6221) 515 1555

Sales Trading cont'd

 Suhaida Samsudin (Malaysia)
 (60

 Michael Santos (Philippines)
 (60

 Chris Reale (New York)
 (1

 Marc Rosa (New York)
 (1

 Justin Morrison (Singapore)
 (68

 Daniel Clarke (Taiwan)
 (86

 Brendan Rake (Thailand)
 (66

 Mike Keen (UK/Europe)
 (44

(603) 2059 8888 (632) 857 0813 (1 212) 231 2555 (1 212) 231 2555 (65) 6601 0288 (8862) 2734 7580 (662) 694 7707 (44 20) 3037 4905